US 12,071,481 B2
Anti-CD47 antibodies and uses thereof
Louis Jefferson, Huntersville, NC (US); and Metasebya Solomon, Los Angeles, CA (US)
Assigned to D-10 Therapeutics, Inc., Torrance, CA (US)
Filed by D-10 Therapeutics, Inc., Torrance, CA (US)
Filed on Dec. 23, 2021, as Appl. No. 17/560,763.
Claims priority of provisional application 63/129,716, filed on Dec. 23, 2020.
Prior Publication US 2022/0204613 A1, Jun. 30, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 7/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 7/00 (2018.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)] 22 Claims
 
1. An anti-CD47 antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein:
(a) the VH domain amino acid sequence comprises HCDR1 of SEQ ID NO: 162, HCDR2 of SEQ ID NO: 216 and HCDR3 of SEQ ID NO: 59; and the VL domain amino acid sequence comprises LCDR1 of SEQ ID NO: 75, LCDR2 of SEQ ID NO: 77 and LCDR3 of SEQ ID NO: 115;
(b) the VH domain amino acid sequence comprises HCDR1 of SEQ ID NO: 15, HCDR2 of SEQ ID NO: 17 and HCDR3 of SEQ ID NO: 19; and the VL domain amino acid sequence comprises LCDR1 of SEQ ID NO: 35, LCDR2 of SEQ ID NO: 37 and LCDR3 of SEQ ID NO: 39;
(c) the VH domain amino acid sequence comprises HCDR1 of SEQ ID NO: 55, HCDR2 of SEQ ID NO: 57 and HCDR3 of SEQ ID NO: 59; and the VL domain amino acid sequence comprises LCDR1 of SEQ ID NO: 75, LCDR2 of SEQ ID NO: 77 and LCDR3 of SEQ ID NO: 79;
(d) the VH domain amino acid sequence comprises HCDR1 of SEQ ID NO: 94, HCDR2 of SEQ ID NO: 96 and HCDR3 of SEQ ID NO: 98; and the VL domain amino acid sequence comprises LCDR1 of SEQ ID NO: 112, LCDR2 of SEQ ID NO: 77 and LCDR3 of SEQ ID NO: 115;
(e) the VH domain amino acid sequence comprises HCDR1 of SEQ ID NO: 94, HCDR2 of SEQ ID NO: 96 and HCDR3 of SEQ ID NO: 131; and the VL domain amino acid sequence comprises LCDR1 of SEQ ID NO: 112, LCDR2 of SEQ ID NO: 77 and LCDR3 of SEQ ID NO: 149;
(f) the VH domain amino acid sequence comprises HCDR1 of SEQ ID NO: 162, HCDR2 of SEQ ID NO: 163 and HCDR3 of SEQ ID NO: 59; and the VL domain amino acid sequence comprises LCDR1 of SEQ ID NO: 75, LCDR2 of SEQ ID NO: 77 and LCDR3 of SEQ ID NO: 115; or
(g) the VH domain amino acid sequence comprises HCDR1 of SEQ ID NO: 162, HCDR2 of SEQ ID NO: 163 and HCDR3 of SEQ ID NO: 59; and the VL domain amino acid sequence comprises LCDR1 of SEQ ID NO: 35, LCDR2 of SEQ ID NO: 37 and LCDR3 of SEQ ID NO: 182.